Cargando…

Nanosecond-pulsed DBD plasma treatment on human leukaemia Jurkat cells and monoblastic U937 cells in vitro

Plasma therapy offers an exciting and novel way of cancer treatment. Specifically, it is shown that Jurkat death rates are closely governed by the plasma treatment time. However, apart from time, alterations to different parameters of treatment process may yield better results. Here, Dielectric barr...

Descripción completa

Detalles Bibliográficos
Autores principales: Erfani, Rasool, Carmichael, Cameron, Sofokleous, Thea, Wang, Qiuyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012873/
https://www.ncbi.nlm.nih.gov/pubmed/35428374
http://dx.doi.org/10.1038/s41598-022-10056-8
_version_ 1784687883342315520
author Erfani, Rasool
Carmichael, Cameron
Sofokleous, Thea
Wang, Qiuyu
author_facet Erfani, Rasool
Carmichael, Cameron
Sofokleous, Thea
Wang, Qiuyu
author_sort Erfani, Rasool
collection PubMed
description Plasma therapy offers an exciting and novel way of cancer treatment. Specifically, it is shown that Jurkat death rates are closely governed by the plasma treatment time. However, apart from time, alterations to different parameters of treatment process may yield better results. Here, Dielectric barrier discharge (DBD) reactors excited by a nanosecond-pulse energy source are used to investigate cell viability for longer exposure times as well as the effects of polarity of reactor on treatment. Plasma discharge regimes are discussed and assessed using imaging and thermal imaging methods. We found that by changing the polarity of reactor i.e. changing the direction of plasma discharge, the plasma discharge regime changes influencing directly the effectiveness of treatment. Our results showed that ns-DBD− reactor could induce both apoptosis and necrosis of human Jurkat and U937 cells, and this cytotoxic effect of plasma was not completely antagonized by N-acetyl cysteine. It indicates that plasma could induce ROS-independent cell death. Gene expression analyses revealed that p53, BAD, BID and caspase 9 may play vital roles in plasma caused cell death. In addition, our findings demonstrate how different parameters can influence the effectiveness of our reactors. Our assay reveals the custom ability nature of plasma reactors for hematologic cancer therapy and our findings can be used for further development of such reactors using multi-objective optimisation techniques.
format Online
Article
Text
id pubmed-9012873
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90128732022-04-18 Nanosecond-pulsed DBD plasma treatment on human leukaemia Jurkat cells and monoblastic U937 cells in vitro Erfani, Rasool Carmichael, Cameron Sofokleous, Thea Wang, Qiuyu Sci Rep Article Plasma therapy offers an exciting and novel way of cancer treatment. Specifically, it is shown that Jurkat death rates are closely governed by the plasma treatment time. However, apart from time, alterations to different parameters of treatment process may yield better results. Here, Dielectric barrier discharge (DBD) reactors excited by a nanosecond-pulse energy source are used to investigate cell viability for longer exposure times as well as the effects of polarity of reactor on treatment. Plasma discharge regimes are discussed and assessed using imaging and thermal imaging methods. We found that by changing the polarity of reactor i.e. changing the direction of plasma discharge, the plasma discharge regime changes influencing directly the effectiveness of treatment. Our results showed that ns-DBD− reactor could induce both apoptosis and necrosis of human Jurkat and U937 cells, and this cytotoxic effect of plasma was not completely antagonized by N-acetyl cysteine. It indicates that plasma could induce ROS-independent cell death. Gene expression analyses revealed that p53, BAD, BID and caspase 9 may play vital roles in plasma caused cell death. In addition, our findings demonstrate how different parameters can influence the effectiveness of our reactors. Our assay reveals the custom ability nature of plasma reactors for hematologic cancer therapy and our findings can be used for further development of such reactors using multi-objective optimisation techniques. Nature Publishing Group UK 2022-04-15 /pmc/articles/PMC9012873/ /pubmed/35428374 http://dx.doi.org/10.1038/s41598-022-10056-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Erfani, Rasool
Carmichael, Cameron
Sofokleous, Thea
Wang, Qiuyu
Nanosecond-pulsed DBD plasma treatment on human leukaemia Jurkat cells and monoblastic U937 cells in vitro
title Nanosecond-pulsed DBD plasma treatment on human leukaemia Jurkat cells and monoblastic U937 cells in vitro
title_full Nanosecond-pulsed DBD plasma treatment on human leukaemia Jurkat cells and monoblastic U937 cells in vitro
title_fullStr Nanosecond-pulsed DBD plasma treatment on human leukaemia Jurkat cells and monoblastic U937 cells in vitro
title_full_unstemmed Nanosecond-pulsed DBD plasma treatment on human leukaemia Jurkat cells and monoblastic U937 cells in vitro
title_short Nanosecond-pulsed DBD plasma treatment on human leukaemia Jurkat cells and monoblastic U937 cells in vitro
title_sort nanosecond-pulsed dbd plasma treatment on human leukaemia jurkat cells and monoblastic u937 cells in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012873/
https://www.ncbi.nlm.nih.gov/pubmed/35428374
http://dx.doi.org/10.1038/s41598-022-10056-8
work_keys_str_mv AT erfanirasool nanosecondpulseddbdplasmatreatmentonhumanleukaemiajurkatcellsandmonoblasticu937cellsinvitro
AT carmichaelcameron nanosecondpulseddbdplasmatreatmentonhumanleukaemiajurkatcellsandmonoblasticu937cellsinvitro
AT sofokleousthea nanosecondpulseddbdplasmatreatmentonhumanleukaemiajurkatcellsandmonoblasticu937cellsinvitro
AT wangqiuyu nanosecondpulseddbdplasmatreatmentonhumanleukaemiajurkatcellsandmonoblasticu937cellsinvitro